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Abstract
Objectives To explore the percentage enhancement wash-
out ratio (PEW) and relative PEW (RPEW) of low-dose
multi-phasic computed tomography (CT) in distinguishing
benign from malignant parotid gland tumours.
Methods This study was approved by the ethics committee,
and informed patient consent was obtained. 51 patients with
parotid tumours proven by histopathology received CT,
including 18 with pleomorphic adenomas, 14 with War-
thin’s tumours and 19 with malignant tumours. Size and
attenuation of parotid tumours were measured. Compared
with 5-min attenuation, the 30-s and 90-s PEW (PEW30,
PEW90) and RPEW (RPEW30, RPEW90) were calculated.
Results There was a significant difference in PEW30,
RPEW30,P E W 90 and RPEW90 in the parotid neoplasms
groups (P<0.01), and statistical significance existed simul-
taneously in pleomorphic adenomas vs malignant tumours
and Warthin’s tumours vs malignant tumours according to
SNK-q test. The optimal diagnosis results of malignancy with
100% specificity (32/32) was obtained by using a combina-
tion of the following criteria: −70%>PEW30<36%, −30%>
PEW30<19%, PEW90>12%, and the sensitivity (74%) for
diagnosis of malignancy was yield.
Conclusions Wash-out ratio may assist in differentiating the
benign from malignant parotid gland tumours. Combining
the percentage of enhanced wash-out ratios of CT protocols
can yield diagnostic results for malignancy.
Keywords Low-dose CT·parotid gland neoplasm.
Dynamic contrast-enhanced CT.Percentage enhancement
wash-out ratio
Introduction
Salivary gland neoplasms account for approximately 3% of
all head and neck tumours. About 70% of all salivary gland
neoplasms occur in the parotid gland [1, 2]. Several studies
[3–6] have investigated the value of computed tomography
(CT) in distinguishing parotid gland tumours. The results of
some documents have demonstrated that CT could identify
patients with pleomorphic adenomas, Warthin’s tumours
and malignant tumours, and evaluate the extent of parotid
gland tumours. Moreover, detailed information on signal
intensity and wash-out ratio in parotid gland tumours by
contrast-enhanced MRI has been reported for pleomorphic
adenomas, Warthin’s tumours, and malignant tumours [7–
10]. To our knowledge, very few data on the percentage
enhanced wash-out ratio in low-dose multiple-phasic CT
among pleomorphic adenomas, Warthin’s tumours and
malignant tumours have already been analysed. Conse-
quently, this study focused on strategies to differentiate
benign from malignant neoplasms by measuring the
percentage enhanced washout ratio of patients with parotid
gland tumours.
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Study cohort
This study was approved by our institutional review board,
and informed patient consent was obtained before study
participation according to institutional and native guide-
lines. Between August 2002 and December 2009, the 51
patients (29 men and 22 women aged 25–68 years; mean
age, 44±8.5 years) fulfilled the criteria for inclusion. 18
patients (13 men and 5 women aged 26–58 years; mean
age, 41±7.4 years) had pleomorphic adenomas, and 14
(6 men and 8 women aged 33–78 years; mean age, 55±
9.1 years) had Warthin’s tumours. 19 patients (11 men and
8 women aged 25–68 years; mean age, 46±8.6 years) had
malignancies, including adenoid cystic carcinoma (n=6),
mucoepidermoid carcinoma (n=4), carcinoma ex pleomor-
phic adenoma (n=2), ductal carcinoma (n=2), acinic cell
carcinoma (n=1), sebaceous carcinoma (n=1), lymphoma
(n=2) and squamous carcinoma (n=1). Diagnoses for 51
patients with parotid gland neoplasms were established
when histological proof was obtained at surgery.
Imaging protocol
All patients underwent multi-detector CT (LightSpeed ultra;
GE Medical Systems, USA). All patients gave written
informed consent to undergo CT. To reduce the radiation
doses and preserve the diagnostic quality of the imaging, the
protocol for the helical CT examinations performed in 51
patients with acquisition parameters: 5-mm slice, a 7.5 mm/s
table speed, 120 kVp, 60 mA, a 0.8-s rotation time, a pitch of
0.625, and 5-mm reconstruction intervals before and after the
intravenous bolus injection ofcontrastmaterial(Ultravist300,
Schering, Germany; 300 mg of iodine per millilitre). Imaging
began at the skull base and continued to the thyroid cartilage.
To optimise the reproducibility of the starting measurements,
each image was obtained while the patient held their breath
and stopped deglutition.
First, a non-enhanced image was obtained through the
parotid gland. An 18- or 20-gauge intravenous catheter was
placed in an antecubital vein and manually tested by rapidly
infusing 10 ml of saline. Subsequently, 80–120 ml of non-
ionic contrast material (1.5 ml per kg) was administered at
2 ml/s by using a power injector (Medrad, Warrendale, PA,
USA). In all patients, the second, third, and fourth images
were obtained 30 s, 90 s, and 5 min after the start of the
contrast material injection respectively. The imaging proto-
col was preprogrammed so that these images were obtained
by using the same parameters that were used to obtain the
non-enhanced images. The images were obtained with
standard soft-tissue settings (window width, 300 HU;
window level, 40 HU).
Image and data analyses
The CT were interpreted and values of diagnostic param-
eters were measured by using Advantage Windows 4.2 (GE
Medical systems, USA). These tasks were performed by
two radiologists who were experienced in performing CTof
the parotid glands. Two radiologists had no knowledge of
the clinical or histological findings, and they worked
independently without consultation with one another.
To determine the size of the masses, a distance cursor
was used to measure the diameter in the transverse plane.
The section of the largest square area of the parotid gland
mass was used for analysis. The measurements obtained by
the two radiologists were averaged.
The attenuation values of all parotid gland masses
detected at CT were measured by using circular region-of-
interest (ROI) cursors placed over the area of disease (the
biggest mass was selected if multiple lesions were present).
The ROI circle was made as large as possible with
sufficient margin to avoid partial volume effects. Cystic,
necrotic and haemorrhagic components, as well as calcifi-
cations of the parotid gland masses, were excluded if they
were present. Necrosis was defined as a region (within the
mass) with an attenuation value similar to that of water
(−20HU ~ 20HU) on the non-enhanced CT. Calcification
was defined as a region with an attenuation value greater
than 120 HU on non-enhanced CT. Attenuation values were
recorded and averaged for final data analysis.
We calculated the following diagnostic parameters for all
masses: the absolute percentage enhanced wash-out ratio
(PEW) was calculated as PEW30 ¼ 1   A300   AN ðÞ = ½
ðA30   ANÞ    100 or PEW90 ¼ 1   A300   AN ðÞ = A90  ð ½
ANÞ    100, and the relative percentage enhanced wash-out
ratio (RPEW30 or RPEW90) was calculated as follows:
A30   A300 ðÞ =A30 ½    100 or A90   A300 ðÞ =A90 ½    100 ,
where AN is the attenuation on non-enhanced CT, A30 or
A90 is 30 or 90-s enhanced attenuation, and A300 is 5-min
enhanced attenuation.
Statistical analyses
Statistical analyses were performed with software (SPSS
13.0; Chicago, IL, USA). Primary statistical analysis of the
pooled data (mean±standard deviations) was performed
with the analysis of variance (ANOVA) to determine mean
differences in objective measurements of parotid gland
tumour groups by helical CT, followed by Student-
Newman-Keuls –q (SNK-q) test for multiple comparisons.
P<0.01 was considered to indicate statistical significance.
Receiver operating characteristic (ROC) analysis was
employed to investigate the differentiation capability of
the diagnostic parameters value for distinguishing malig-
nant from benign parotid tumours when significant differ-
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versus pleomorphic adenoma groups and malignant tumour
versus Warthin’s tumour groups. The optimal threshold
value, determined by the maximal Youden index defined as
sensitivity plus specificity minus 1, was selected and the
area under the ROC (AUC) was calculated. Then,
corresponding sensitivity and specificity were calculated
for individual parameters. In addition, we examined
whether the diagnostic accuracy could be improved by
combining these individual diagnostic parameters.
Results
Mass size
The biggest range of pleomorphic adenoma diameters was
from 0.8 cm to 8.1 cm, compared with those of Warthin’s
tumours (2.2–3.3 cm) and malignant tumours (1.9–4.5 cm).
There were no significant differences in mean diameters
among the pleomorphic adenoma, Warthin’s tumour and
malignant tumour groups (P=0.41).
Non-enhanced CT, dual contrast-enhanced CT
and 5-minute delay contrast-enhanced CT
The means and the ranges of attenuation of different groups
of parotid gland tumours are listed in Table 1. There were
no significant differences among the mean attenuations of
pleomorphic adenomas, Warthin’s tumours and malignant
tumours on non-enhanced CT (P=0.047) and the fourth CT
(P=0.21). Although significant differences were found in
the attenuation of the pleomorphic adenomas, Warthin’s
tumours and malignant tumours groups (P<0.01) on the
second and the third CT, there were simultaneously no
differences between pleomorphic adenomas vs malignant
tumours and Warthin’s tumours vs malignant tumours by
SNK-q test.
Sixty-two masses in 51 patients were detected by the
identical imaging protocol, including 18 pleomorphic
adenomas (n=18), 18 Warthin’s tumours (n=14) and 26
malignant tumours (n=19). Calcifications were found in
two pleomorphic adenomas, but not in any of the Warthin’s
tumours or malignant tumours. 8 of the 14 Warthin’s
tumours, 6 of the 18 pleomorphic adenomas and 4 of the 19
malignant tumours had regions of necrosis.
Diagnostic ratios
Diagnostic ratios of parotid gland neoplasms are listed in
Table 2. There were significant differences in PEW30 and
RPEW30 among these parotid gland tumour groups (P<
0.01). By using a threshold value of −70% PEW30 and −30%
RPEW30 between pleomorphic adenomas and malignant
tumours, the sensitivity could reach up to 89% and 89%
respectively, but the specificity was low for malignant
tumours. At the threshold value of 36% PEW30 and 19%
RPEW30 between Warthin’s tumours and malignant tumours,
the sensitivity-specificity ratios were 100%:93% and
100%:86% respectively.
There were significant differences in PEW90 and
RPEW90 among the three parotid gland tumour groups.
Applying a threshold value of 12% PEW90 and 4%
RPEW90 between pleomorphic adenomas and malignant
tumours, the ratios of sensitivity to specificity were 95/89%
and 95/94%. At the cut-off value of 31% PEW90 between
Warthin’s tumours and malignant tumours, the ratio of
sensitivity-specificity was 63/71%. The optimal threshold
values of RPEW90 were not obtained between the Warthin’s
tumours and malignant tumours (Table 3).
To obtain 100% specificity and maximal sensitivity in
malignant glandtumours byusingthe combination ofPEW30,
RPEW30 and PEW90 (Table 4), we obtained the threshold
value criteria as follows: −70%>PEW30<36%, −30%>
PEW30<19%, PEW90>12%, and 74% sensitivity was
yielded (Fig. 1a–e).
Discussion
Parotid gland masses are common: about 80% of parotid
tumours are benign, and most of them, about 60%, are
Table 1 CT parameters for each group and statistical results of ANOVA
CT Parameters Pleomorphic adenomas (n=18) Warthin’s tumours (n=14) Malignant tumours (n=19) P value
*
Non-enhanced attenuation (HU) 37±6.3(28–46) 42±5.6(33–49) 38±5(32–48) 0.047
30-s enhanced attenuation (HU) 57±11 (32–75) 93±22(38–120) 69±10(52–88) <0.01
90-s enhanced attenuation (HU) 69±15(31–95) 80±16(37–105) 88±18(56–126) <0.01
5-min enhanced attenuation (HU) 79±18(30–102) 69±13(35–87) 76±13(49–101) 0.21
Data are mean ± standard deviations, with ranges in parentheses
The P value levels are for comparison among pleomorphic adenomas, Warthin’s tumours and malignant tumours groups by using the analysis of
variance (P<0.01)
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(about 10%). Malignant tumours comprise about 15 to
30% of all kinds of parotid tumours. The most common
parotid gland malignancy is mucoepidermoid carcinoma
[11]. The cystic adenoid carcinoma is the second most
frequent malignancy; other parotid tumours include acinar
cell carcinomas, adenocarcinoma not otherwise specified
(NOS), lymphoma, and the carcinoma ex pleomorphic
adenoma [12].
The main symptom in patients with parotid neoplasms is a
lump in the parotid gland area. Other symptoms such as pain,
facial palsy and skin ulcers may emerge in malignancies.
According to the extent of the tumour, partial or total
parotidectomyisthemainstreamtreatmentmeasureforbenign
and malignant parotid tumours. Radiotherapy may aid in
malignant cases as adjuvant therapy; chemotherapy is rarely
applied. Parotid gland neoplasm recurrence rates of local,
regional and distant are 40%, 15% and 11%, respectively.
Patients with recurrence have a poor prognosis [13].
The use of CT and MR imaging has resulted in the
detection of parotid gland masses. More recent literature
[3–10, 14, 15] has focused on different approaches to
characterising parotid masses, including assessing lesion
size, describing morphological criteria, measuring attenua-
tion or signal intensity, calculating the contrast material
change of single or dual enhancement. Kress et al. [14]
have demonstrated that CT sialography is dispensable in the
diagnosis of suspected malignant tumours. Casselman and
Mancuso [15] reported that CT and MR imaging were the
first choices for providing the same diagnostic information
in all cases of parotid gland neoplasms. Choi et al. [4]
demonstrated that the ratio of CT numbers in enhancement
patterns and the attenuation change was significantly
different between Warthin’s tumours and pleomorphic
adenomas, and between Warthin’s tumours and malignant
tumours. Yabuuchi et al. [7] showed that parotid neoplasms
could be differentiated by the 120 s of MR time of peak
enhancement and a 30% wash-out ratio (WR), and benign
and malignant tumours were recognised by a combined
classification of time signal intensity curve and 30% WR.
However, to our knowledge, there are no reports of
comparisons for benign and malignant parotid gland
tumours by the attenuation and percentage enhancement
wash-out ratios.
The results of our study indicated that the mean
attenuation values of pleomorphic adenomas were similar
to those of malignant tumours, but lower than those of
Warthin’s tumours on non-enhanced CT. However, there
was considerable overlap in attenuation among pleomor-
phic adenomas, Warthin’s tumours and malignant tumours,
and, hence, there was no difference between benign and
malignant parotid gland tumours (P=0.047). In our limited
data, multiple masses were found in patients with Warthin’s
tumours and malignant tumours. Necrotic portions were
Table 2 Diagnostic ratios for each group and statistical results of ANOVA
CT Parameters Pleomorphic adenomas (n=18) Warthin’s tumours (n=14) Malignant tumours (n=19) P value
*
PEW30 (%) −188±341(−1400–67) 49±11(29–75) −30±46(−121–33) <0.01
RPEW30 (%) −38±32(−93–18) 24±8(8–39) −11±18(−51–18) <0.01
PEW90 (%) −39±98(−411–50) 32±13(12–67) 26±10(3–47) <0.01
RPEW90 (%) −14±21(−80–9) 13±5(5–20) 14±1(1–24) <0.01
Data are mean ± standard deviations, with ranges in parentheses
The P value levels are for comparison among pleomorphic adenomas, Warthin’s tumours, and malignant tumours groups by using the analysis of
variance (P<0.01)
Parameters AUC
a Optimal cut-off value Sensitivity (%) Specificity (%)
Differentiation between pleomorphic adenomas and malignant tumours
b
PEW30 (%) 0.75(0.58–0.91) −70 89(17/19) 56(10/18)
RPEW30 (%) 0.76(0.60–0.92) −30 89(17/19) 61(11/18)
PEW90 (%) 0.92(0.82–1.00) 12 95(18/19) 89(16/18)
RPEW90 (%) 0.98(0.94−1.00) 4 95(18/19) 94(17/18)
Differentiation between Warthin’s tumours and malignant tumours
b
PEW30 (%) 0.99(0.98–1.00) 36 100(19/19) 93(13/14)
RPEW30 (%) 0.98(0.95–1.00) 19 100(19/19) 86(12/14)
PEW90 (%) 0.64(0.45–0.84) 31 63(12/19) 71(10/14)
RPEW90 (%) 0.47(0.27–0.68) –– –
Table 3 ROC analysis of
percentage enhanced wash-out
ratios of pleomorphic adenomas
(n=18), Warthin’s tumours
(n=14), and malignant tumours
(n=19) of the parotid gland
aData in parentheses are 95%
confidence intervals
bSensitivity and specificity in the
identification of malignant tumours.
Data in parentheses are numbers
used to calculate percentages
Eur Radiol (2011) 21:1692–1698 1695viewed in three types of parotid tumours. Calcifications
were detected in some pleomorphic adenomas, we pre-
sumed that the finding was related to ossification of
cartilage structure in pleomorphic adenomas.
From our limited data, the mean attenuation of Warthin’s
tumour attained the peak of enhancement during 30-s
imaging, and most malignant tumours attain peak attenua-
tion in 90-s imaging, but significant differences did not
exist simultaneously between the malignant tumour vs the
pleomorphic adenoma groups and the malignant tumour vs
the Warthin’s tumour groups for a sustainable overlap. On
the 5-min delay imaging, there was no difference among
the parotid gland tumour groups. The discrepancy of mean
attenuations between ours and a previous study [4] was
attributed to CT parameters, such the total volume of
contrast material and the injection rate of contrast material.
Our findings suggested that reliable cut-off values were not
helpful in differentiating benign from malignant tumours of
the parotid gland on non-enhanced, 30-s, 90-s and 5-min
imaging series.
The PEW and RPEW are the percentage enhanced wash-
out ratio of enhanced attenuation according to the timing of
the early and delayed imaging. Our results showed that
there were significant differences in PEW and RPEW of
parotid gland tumour groups, and significant differences
simultaneously in the malignant tumour versus pleomorphic
adenoma groups and the malignant tumour versus War-
thin’s tumour groups.
From 30-s to 5-min helical CT of parotid gland tumours,
applying the threshold value of −70% of PEW30 and −30%
of RPEW30 between pleomorphic adenomas and malignant
tumours, 89% and 89% of sensitivity, 56% and 61% of
specificity were procured for the diagnosis of malignant
tumours, relatively, 36% of PEW30 and 19% of RPEW30
between Warthin’s tumours and malignant tumours, 93%
and 86% of specificity company with 100% sensitivity was
diagnosed for malignancies. Likewise, from 90-s to 5-min
helical CT of parotid gland tumours, using an optimal cut-
off value of 12% of PEW90 and 4% of RPEW90 between
pleomorphic adenomas and malignant tumours, 95% and
95% of sensitivity, 89% and 94% of specificity were
obtained for diagnosis of malignant tumours, and 31% of
PEW90 between Warthin’s tumours and malignant tumours,
63% of sensitivity and 71% of specificity were diagnosed
for malignancies; conversely, with RPEW90 there was much
more of an overlap between Warthin’s tumours and
malignant tumours.
Although, the enhanced wash-out ratio of tumours was
altered for CT parameters [16], for instance, volume,
injection rate and time of contrast material, the foundation
of different enhanced wash-out ratios was determined by
many inherent traits of parotid gland neoplasms, such as
angiogenesis [17, 18]. With pleomorphic adenoma it is
widely accepted that both epithelial and mesenchymal
(myxoid, hyaline, chondroid, osseous) elements often arise
from the same cell clone, which may be a myoepithelial or
ductal reserve cell [19, 20]. Warthin’s tumours, also known
as papillary cystadenoma lymphomatosum, consist of an
epithelial, monomorphic, oncocytic component and a
lymphoid stroma [21, 22]. Parotid gland malignancies
include diverse tumour types, with the mucoepidermoid
carcinoma being the most common tumour. The incidence
of adenocarcinoma NOS, the acinar cell carcinoma, the
cystic adenoid carcinoma, the carcinoma ex pleomorphic
adenoma, and the undifferentiated carcinoma is obviously
disparate in different research [23–27]. The enhancement
wash-out ratio may mirror different histological compo-
nents of tumour cells and different architecture of tumoral
angiogenesis in parotid gland tumours. Hereby, the
percentage-enhanced change could provide the pathological
information and differentiate benign from malignant
tumours in the parotid gland.
Although we set the optimal threshold criteria to obtain
diagnostic values of individual percentage enhanced wash-
out ratios, they had much more distinction with regard to
sensitivity and specificity. We believe that identification of
patients with malignant parotid tumours is more important
than missing benign parotid tumours. For this reason, we
reanalysed cut-off values of the individual percentage
enhanced washout ratios to yield 100% specificity, and
examined whether a combination of some of these
parameters improved the sensitivity. We tried to employ
one or two of three percentages enhanced changes to get
100% specificity, but failed. The final research demon-
Table 4 Best diagnostic values for percentage enhanced wash-out ratios for differentiating benign from malignant tumours of the parotid gland
Parameter Threshold criterion Parotid gland tumours
Sensitivity (%) Specificity (%)
PEW30 (%) −70> and <36 89(17/19) 78(25/32)
RPEW30 (%) −30> and <19 89(17/19) 69(22/32)
PEW90 (%) >12 84(16/19) 72(23/32)
Combined threshold values –- 74(14/19) 100(32/32)
Sensitivity and specificity in the identification of malignant tumours. Data in parentheses are numbers used to calculate percentages
1696 Eur Radiol (2011) 21:1692–1698strated that a parotid gland tumour was defined as a
malignant mass when the following parameters were
satisfied: −70%>PEW30<36%, −30%>PEW30<19%,
PEW90>12%, and 74% sensitivity.
Our study had some limitations. First, parotid gland
malignancies include various types of tumours, such as
mucoepidermoid carcinoma, adenoid cystic carcinoma, carci-
noma ex pleomorphic adenoma, squamous cell carcinoma,
acinic cell carcinoma, duct carcinoma and lymphoma.
Second, some selected masses were biased in Warthin’s
tumours and malignant tumours, only the largest masses of
the parotid gland were evaluated. Third, because of the small
sample size and overlap in data among the three study
subgroups, validation of the proposed cut-off values of CT
diagnostic parameters needs to be performed in a larger scale
trial. Lastly, if multiple-phasic CTwere performed along with
a diagnostic study, the patients would be exposed to an
additional radiation dose.
In summary, the percentage wash-out ratios in contrast
material-enhanced CT may reflect various characters of
parotid gland neoplasms, and assist in differentiating the
benign from malignant tumours. Combining the percentage
enhanced wash-out ratios of the CT protocol can yield
diagnostic results in malignant parotid gland tumours.
Fig. 1 a–e Transverse
CT obtained in a 65-year-old
man with mucoepidermoid
carcinoma. a Non-enhanced CT
obtained at level of the right
parotid gland shows ill-defined
hypo-attenuation mass relative
to the jugomaxillary muscle.
30-s and 90-s contrast enhance-
ment, 5-min delay (b, c, d)
obtained at the same level as in
a. The tumour has heteroge-
neous enhancement on the 30-s
(b), 90-s (c) and the 5-min delay
phase (d) images. Tumour at-
tenuation had 39.2 HU in a,
68.4 HU in b, 76.7 HU in c, and
67.4 HU in d. Thus, the absolute
percentage enhanced wash-out
ratio of malignant tumours is
3.4% of PEW30 and 24.8% of
PEW90, and the relative per-
centage enhanced wash-out ratio
of the malignancy is 1.5% of
RPEW30 and 12.1% of
RPEW90. e Surgical histopa-
thology revealed mucoepider-
moid carcinoma; H&E×100
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